Search

Editas Medicine Inc

Geschlossen

BrancheGesundheitswesen

3.24

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.96

Max

3.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-25M

Verkäufe

-22M

2.8M

EPS

-0.26

Gewinnspanne

-882.444

Angestellte

87

EBITDA

-18M

-23M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+118.18% upside

Dividenden

By Acuity

Nächstes Ergebnis

10. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

266M

560M

Vorheriger Eröffnungskurs

3.24

Vorheriger Schlusskurs

3.24

Nachrichtenstimmung

By Acuity

17%

83%

42 / 342 Ranking in Healthcare

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Juli 2026, 23:06 UTC

News

PepsiCo shares are lower in after-market hours following a downgrade to Hold by Citi, with the price target reduced to $145 from $170.

10. Juli 2026, 23:01 UTC

News

Cognizant Technology Solutions received court approval for a $5.5 million settlement in a stockholder lawsuit, with shares trading higher in after-market hours.

10. Juli 2026, 20:13 UTC

ETF Constituents
News
Correlated Moves

Vanguard Large-Cap ETF is trading lower in after-market hours, influenced by slight losses in top holdings META, AAPL, ABBV, MA, and NVDA.

10. Juli 2026, 20:07 UTC

News
Correlated Moves

Ethereum is gaining as Circle Internet Group receives approval for a national trust bank, boosting interest in digital assets amid geopolitical tensions.

10. Juli 2026, 20:07 UTC

News

Costco Wholesale shares are higher today, recovering from earlier losses despite concerns over moderating growth and sustainability amid easing fuel prices.

10. Juli 2026, 20:07 UTC

News
Social Media

Micron Technology shares are lower amid a semiconductor sector selloff, despite announcing over $250 billion in U.S. investment for AI memory chips.

10. Juli 2026, 20:07 UTC

News
Social Media
Event

Netflix Inc shares are lower amid concerns about declining subscriber engagement. The company is exploring strategies to enhance viewer interest, including live TV channels.

10. Juli 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher as Circle Internet Group gains approval for a national trust bank focused on digital asset custody services. Ethereum also shows notable increases.

10. Juli 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher since Thursday's close, supported by Circle Internet Group's approval for a national trust bank focused on digital asset custody services.

10. Juli 2026, 20:07 UTC

Correlated Moves
News

Ethereum is gaining amid increased market interest following Circle Internet Group's trust bank approval. Geopolitical tensions are also driving investors toward cryptocurrencies.

10. Juli 2026, 20:06 UTC

News

Autodesk Inc shares are lower today following a negative report from StockStory, which advises avoiding the stock due to slower revenue growth and high payback periods.

10. Juli 2026, 20:06 UTC

News

United Airlines shares are lower amid concerns following Delta's strong earnings report, which raised expectations for upcoming results but highlighted pricing power challenges.

10. Juli 2026, 20:06 UTC

Correlated Moves
Social Media
News

Applied Materials shares advance as Needham raises price target to $740 and Stifel lifts its target to $650, reflecting strong demand in the semiconductor sector.

10. Juli 2026, 20:03 UTC

News
Social Media

NVIDIA shares are higher today as Morgan Stanley reaffirms its Overweight rating and U.S. eases AI chip export curbs to the UAE.

10. Juli 2026, 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

10. Juli 2026, 20:02 UTC

News
Social Media

Fox Corp shares are higher, supported by record FIFA World Cup viewership and an upgrade to Buy from Rothschild Redburn, raising the price target to $71.

10. Juli 2026, 20:01 UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

10. Juli 2026, 19:56 UTC

Social Media
News

Dollar Tree shares are higher after a positive UBS assessment, signaling an inflection point for the retailer amid cautious market sentiment ahead of key economic data.

10. Juli 2026, 19:51 UTC

Social Media
News

Take-Two Interactive is under pressure amid sector weakness, with a recent report advising against the stock due to limited cash flow and declining sales projections.

10. Juli 2026, 19:47 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Small-Cap ETF is lower amid ongoing geopolitical tensions and declines among key holdings, including SRPT, AXON, NTRA, LAMR, and IONS.

10. Juli 2026, 19:47 UTC

News
Social Media

Tesla Inc's stock is higher, supported by increased buying interest and strong Model Y sales in China, with shares reaching an intraday high of $407.85.

10. Juli 2026, 19:47 UTC

News

PayPal Holdings Inc is gaining momentum, driven by strong performance in Venmo and Braintree, alongside a clearer operational framework under CEO Dan Schulman.

10. Juli 2026, 19:47 UTC

News
Social Media

Intel Corp's stock is lower as AMD's data center revenue outpaces Intel's, raising investor concerns amid ongoing profitability challenges.

10. Juli 2026, 19:47 UTC

News

Qualcomm shares are lower at about $188.81 amid mixed options sentiment and a decline in implied volatility ahead of the upcoming earnings report.

10. Juli 2026, 19:47 UTC

Correlated Moves
Social Media
News

Broadcom shares are lower despite a $30 billion agreement with Apple to produce custom silicon components through 2031, amid broader semiconductor industry concerns.

10. Juli 2026, 19:46 UTC

News
Social Media

Rothschild Redburn upgraded Fox Corp to Buy, raising the price target to $71. The stock remains higher since Thursday's close despite earlier session pullbacks.

10. Juli 2026, 19:46 UTC

News

American Airlines Group faces challenges ahead of its earnings report, with shares declining amid cautious sentiment following Delta Air Lines' strong Q2 performance.

10. Juli 2026, 19:41 UTC

Macro News
ETF Constituents
News

FXI is trading higher following Shein's Hong Kong IPO approval, boosting confidence in Chinese equities. Key holdings XIACY and TCOM also show notable returns.

10. Juli 2026, 19:36 UTC

News

CSX shares rise on TD Cowen, JP Morgan upgrades ahead of Q2 report.

10. Juli 2026, 19:36 UTC

News
Social Media

Microsoft shares advanced after Argus reaffirmed a Buy rating, lowering the price target to $510. The stock remains near the upper end of its one-month range.

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

118.18% Vorteil

12-Monats-Prognose

Durchschnitt 7.2 USD  118.18%

Hoch 15 USD

Tief 4 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

5

Buy

1

Halten

1

Sell

Stimmung

By Acuity

42 / 342 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat